CV Sciences Inc (OTCMKTS:CVSI) Demonstrates PlusCBD Products Health Benefits And Tolerability In A Two-Year Study

CV Sciences Inc (OTCMKTS:CVSI) demonstrated the health benefits of PlusCBD products in a two-year trial conducted on millions of customers. The health benefits and safety details of these health supplements are published in the Dietary Supplements Journal.

Hemp-based Cannabidiol as a dietary supplement

The two-year study demonstrates hemp-derived cannabidiol (CBD) as an excellent dietary supplement without any noticeable side effects in several million users. According to the study, it is well-tolerated and safe to use. People, who used even higher dosages of PlusCBD products, have not reported any liver toxicity over a two-year study.

Co-founder of SSS (Supplement Safety Solutions) and a leading author, Stephen Schmitz said it is the first time that CBD dietary supplement is used in the real world conditions without any noticeable safety issues. The data is collected over two years for actual users and finds that it is safe to use.

Improves HDL cholesterol

According to Hector L. Lopez, a lead author, people, who consumed PLusCBD products, improved HDL cholesterol significantly than placebo. Response to stress, sound sleep, and wellness, and life pleasure are considerably improved among the participants, who took PlusCBD products. Lopez said the PlusCBD products demonstrated an excellent safety profile. The group, who are administered these products, have not shown any side effects on the liver. The senior vice president (Clinical/ Regulatory affairs) of CV Sciences, Duffy MacKay, stated the studies supported the health benefits and safety of hemp-based CBD products.

Q1 earnings in 2020

CV Sciences posted $8.3 million in revenues in Q1 2020. Its e-commerce sales jumped by 15% compared to the same period last year and accounted for 24% of the overall revenues.

In January 2020, CV Sciences introduced +PlusCBD oil updated website to improve the navigation experience for users and boost online sales. The USPTO awarded notice of allowance for CV Sciences proprietary nicotine and cannabidiol formulation to cure addiction to smokeless tobacco.

Despite the impact of ongoing coronavirus and challenging market conditions, CV Sciences posted excellent revenues in Q1 2020 and provided guidance. The company reorganized its operations to mitigate the impact of the global health hazards created by COVID-19 and improve performance. CEO, Joseph Dowling said the company is operating its distribution and production facilities to deliver high-quality CBD products derived from hemp to satisfy the growing demand.